Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 20/20 | 0.82 |
| ▸ | TPH2 | Q8IWU9 | 11/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | CCKAR | P32238 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | MC3R | P41968 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309619 | 1.00 | TPH1 (0.82) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL308947 | 1.00 | TPH1 (0.82) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL870655 | 0.92 | TPH1 (0.81) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL870683 | 0.90 | TPH1 (0.85) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL13878219 | 0.89 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL308719 | 0.89 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL308718 | 0.89 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL2364480 | 0.89 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL870344 | 0.89 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 | |
| SCHEMBL29391423 | 0.89 | TPH1 (1.00) | TPH1TPH2ADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984344-B1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2012-09-26 | — | — | EP | claimed |
| US-7723345-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | claimed |
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TERSERA THERAPEUTICS LLC | 2009-02-26 | — | — | US | claimed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | claimed |
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9717727-B2 | Methods of treating and preventing leukemia and other cancers of the blood and bone | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-01 | — | — | US | disclosed |
| US-9150521-B2 | Methods of preventing and treating diabetes by inhibiting serotonin synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150111908-A1 | METHODS OF DIAGNOSING, PREVENTING, AND TREATING BONE MASS DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| US-20140378489-A1 | METHODS OF PREVENTING AND TREATING DIABETES BY INHIBITING SEROTONIN SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2014-12-25 | — | — | US | disclosed |
| US-20140303197-A1 | METHODS OF TREATING AND PREVENTING LEUKEMIA AND OTHER CANCERS OF THE BLOOD AND BONE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-10-09 | — | — | US | disclosed |
| US-8759364-B2 | Methods of treating bone mass diseases | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-06-24 | — | — | US | disclosed |
| US-8629156-B2 | Tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-7875622-B2 | administering to a patient A therapeutically effective amounts of an endothelin receptor antagonist e.g. ambrisentan, bosentan etc. and (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid to treat pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100280054-A1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | TERSERA THERAPEUTICS LLC | 2010-11-04 | — | — | US | disclosed |
| US-7723345-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TERSERA THERAPEUTICS LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2009-01-01 | — | — | US | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111908-A1 | METHODS OF DIAGNOSING, PREVENTING, AND TREATING BONE MASS DISEASES | TPH1, HTR1A, TPH2 | TPH1 1/4885TPH2 3/4885ADORA3 36/4885 |
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TPH1, PAH, TPH2 | TPH1 1/4885TPH2 3/4885ADORA3 567/4885 |
| US-20100280054-A1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | AADAT, HNMT, TPH1 | TPH1 3/4885TPH2 4/4885ADORA3 240/4885 |
| US-20140378489-A1 | METHODS OF PREVENTING AND TREATING DIABETES BY INHIBITING SEROTONIN SYNTHESIS | TPH1, TPH2, HTR1A | TPH1 1/4885TPH2 2/4885ADORA3 183/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | TPH1 3/4885TPH2 4/4885ADORA3 240/4885 |
| US-20140303197-A1 | METHODS OF TREATING AND PREVENTING LEUKEMIA AND OTHER CANCERS OF THE BLOOD AND BONE | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885ADORA3 148/4885 |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885ADORA3 704/4885 |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885ADORA3 629/4885 |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, MAOB | TPH1 1/4885TPH2 2/4885ADORA3 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.